Pulmonary hypertension (PH) is a chronic and progressive disease associated with high blood pressure in the blood vessels, known as the pulmonary arteries, that supply the lungs. It is very difficult to detect and diagnose PH in routine physical exams, given that its symptoms can develop over a…
Pulmonary hypertension (PH) is a rare lung disease characterized by high blood pressure in the pulmonary arteries, which deliver blood from the heart to the lungs. The high pressure causes the heart to work harder to pump blood. This strain can lead to the heart becoming larger and weaker, and…
[vc_row][vc_column][vc_column_text]Pulmonary hypertension (PH) is a severe disease diagnosed when the arteries responsible for transporting blood from the heart to the lungs become constricted. Under normal circumstances, blood is supposed to gather oxygen from the lungs and distribute it to the organs, muscles and body tissue. However, due to the disease, normal blood flow…
Pulmonary hypertension (PH) is a rare disease characterized by abnormally high blood pressure in the pulmonary arteries, which are responsible for transporting blood from the heart to the lungs. As a result of blood vessel narrowing, the heart’s right ventricle needs to work harder to pump blood, becoming enlarged…
Pulmonary hypertension is a chronic and progressive disease characterized by high blood pressure in the pulmonary arteries, the blood vessels of the lungs. There are many potential causes of the disease that, along with how early the disease is diagnosed and when treatment…
Ventavis (iloprost) is an approved therapy for improving the exercise capacity of people with pulmonary arterial hypertension (PAH), and potentially delaying or reducing the worsening of the disease. Ventavis was developed by Schering AG but is now marketed by Bayer in Europe…
Adempas (riociguat) is an approved treatment for the symptoms of pulmonary hypertension. Bayer developed it for chronic thromboembolic pulmonary hypertension, or CTEPH, and pulmonary arterial hypertension, or PAH. How Adempas works Both CTEPH and PAH cause lung…
The European Society of Cardiology (ESC) together with the European Respiratory Society (ERS) recently launched a new treatment algorithm for pulmonary arterial hypertension in its updated pulmonary hypertension guidelines. The amended protocol aims to provide patients with the best chance of a positive clinical outcome despite being diagnosed with…
A research journal recently reviewed the use of balloon pulmonary angioplasty (BPA), a new option for people with inoperable chronic thromboembolic pulmonary arterial hypertension. The work, titled “Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension“ appeared in the July 7, 2015 issue of…
Researchers at Leiden University Medical Center in The Netherlands recently published in the journal Diagnostic and Interventional Radiology a review on the value of computed tomography (CT) as a diagnostic tool for pulmonary embolism. The study is entitled “The role of computed tomography…
Researchers at University of California, San Diego (UCSD) recently published findings in the journal Pulmonary Circulation revealing the prevalence of specific collateral arteries in patients with chronic thromboembolic pulmonary hypertension (CTEPH). The study is entitled “Prevalence of coronary artery-pulmonary artery collaterals in patients with chronic…
Representatives from Bayer HealthCare Pharmaceuticals presented findings at the American Thoracic Society’s (ATS) 2015 International Conference that suggest pulmonary hypertension is more prevalent in patients with pulmonary embolisms than was previously thought. Although the rate may be at least twice as high as previously identified, many patients do not undergo the…
Get regular updates to your inbox.